Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

139.07 -2.00 (-1.42%)
Streaming Delayed Price Updated: 12:34 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stanley Druckenmiller's Top Holding Has Outperformed Its Sector By 252%
Billionaire Stanley Druckenmiller's latest large wager on biotech company Natera Inc has paid off, with his stake now exceeding $575 million. 
Via Benzinga
Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics
From Natera, Inc.
Via Business Wire
Exploring NASDAQ:NTRA's high growth characteristics.
Why the high growth investor may take a look at NATERA INC (NASDAQ:NTRA). 
Via Chartmill
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
From Natera, Inc.
Via Business Wire
Looking Into Natera's Recent Short Interest
 
Via Benzinga
Analyst Expectations For Natera's Future
 
Via Benzinga
Natera Analysts Increase Their Forecasts Following Upbeat Results
 
Via Benzinga
Natera and MyOme Announce Launch of iPRS™ for Breast Cancer Risk Assessment
From Natera, Inc.
Via Business Wire
Clinical Validation Study on Natera’s Fetal RhD NIPT Published in Obstetrics & Gynecology
From Natera, Inc.
Via Business Wire
Natera Announces Medicare Coverage for Prospera™ in Single Lung Transplant Recipients
From Natera, Inc.
Via Business Wire
Earnings Scheduled For November 12, 2024
 
Via Benzinga
How Is The Market Feeling About Natera?
 
Via Benzinga
Exploring NASDAQ:NTRA's high growth characteristics.
NATERA INC (NASDAQ:NTRA) is a candidate for high growth investors. Here's why. 
Via Chartmill
Natera to Present New SignateraTM Data in Multiple Abstracts at the San Antonio Breast Cancer Symposium
From Natera, Inc.
Via Business Wire
Natera Issues Statement on Guardant Health Litigation
From Natera, Inc.
Via Business Wire
Natera Co-Founder and Executive Chairman Matthew Rabinowitz Named 2024 R&D Leader of the Year
From Natera, Inc.
Via Business Wire
Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM
From Natera, Inc.
Via Business Wire
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Stocks Edge Higher, Dollar Hits 1-Year Peak, Bitcoin Soars To $93,000: What's Driving Markets Wednesday?
Wall Street rebounds on inflation report, with consumer discretionary and real estate sectors leading. Senator John Thune elected majority leader. U.S. dollar hits 1-year high. 
Via Benzinga
Topics Economy
Paymentus Posts Better-Than-Expected Earnings, Joins Dave, Honest Company, Natera, CAVA Group And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
Natera Reports Third Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
Stocks Fall On Tariffs Fears, Dollar Hits 6-Month Peak, Yen Tumbles: What's Driving Markets Tuesday?
Wall Street saw the first surge in risk aversion after Donald Trump's election victory last week, as concerns grew over potential tariffs and trade policy shifts spurred by the incoming... 
Via Benzinga
Topics Government World Trade
Natera Announces Completion of Signatera™ Analysis from the CALGB (Alliance)/SWOG 80702 Randomized, Phase III Clinical Trial in Colorectal Cancer
From Natera, Inc.
Via Business Wire
3 Under-the-Radar Healthcare Companies
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains. 
Via MarketBeat
Natera to Participate in Upcoming Investor Conferences
From Natera, Inc.
Via Business Wire
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
Natera to Report its Third Quarter 2024 Results on November 12, 2024
From Natera, Inc.
Via Business Wire
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.